WeTrials
Recruiting

Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

What is this study?

This study is testing a medication called Abemaciclib to see how well it works against advanced bone and soft tissue cancers. Researchers want to help patients whose tumors have specific genetic features by using a targeted drug that blocks cancer cell division.

Who can participate?

You may be eligible if you have an advanced bone or soft tissue cancer that cannot be surgically removed and meets specific tumor testing requirements. Depending on your exact cancer type, you may also need to have tried certain prior treatments like chemotherapy.

What will happen?

If you join, you will take the Abemaciclib medication as pills by mouth twice every day. Your health team will monitor you closely and you will continue taking the medication as long as it is helping and you are doing well.

Where and when?

This study is currently recruiting participants at medical centers in Jacksonville, Florida, Iowa City, Iowa, and St. Louis, Missouri. Your care team can help you figure out if travel to one of these locations works for you.

Key Points
  • 1Tests a targeted pill called Abemaciclib for advanced bone and soft tissue cancers.
  • 2Requires specific tumor characteristics to ensure the medication is a good match for you.
  • 3Currently recruiting patients at select locations in Florida, Iowa, and Missouri.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
ChondrosarcomaOsteosarcomaSoft Tissue Sarcoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.